Threat of Biological Warfare Leads to CSC Contract

by: Matthew Potter
October 1, 2010

Category: Business Line, Canada, Companies, Contract Awards, Countries, CSC, Department of Defense, development program, England, Events, medicine, Services, U.S. Army | RSS 2.0

Since the end of World War II where several different chemical and biological weapons were developed by the Axis and Allies most major nations have invested in defenses against these Weapons of Mass Destruction (WMD). In the Gulf War of the early Nineties the U.S. and its allies faced potential anthrax and other biological agents attacks. One aspect of these defenses has been work on developing drugs to immunize soldiers or treat the diseases.

U.S. defense contractor CSC’s (CSC) business unit, DynPort Vaccine, was awarded a contract by the British government to assist in planning and gaining a European Union (EU) license for a plague vaccine the company has been developing and testing in the U.S.

The vaccine was originally developed at the U.S. Army’s labs at Fort Detrick, MD. DynPort has further developed it and is working with the Food and Drug Administration (FDA) on clinical trials to license it in the U.S. The goal for this vaccine is to provide protection against the plague for U.S., British and Canadian troops. E.U. licensing would also allow it to be used by other nations expanding the market for CSC.

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

Tags: , , , , , , , , ,

| Give a Comment | trackback